Tired of your knee pain?

If you are suffering from osteoarthritis of the knee, consider taking a step in a new direction with the ACTiVION-I clinical trial!

Take the Pre-Screener

Tired of your knee pain?

If you are suffering from osteoarthritis of the knee, consider taking a step in a new direction with the ACTiVION-I clinical trial!

Take the Pre-Screener

What is the ACTiVION-I clinical trial?

The ACTiVION-I study is an osteoarthritis (OA) clinical trial for adults over 40 years of age who have been diagnosed with OA in at least one knee. This study is seeking participants with knee pain caused  by primary OA or “wear-and-tear” OA. The study will evaluate how well the investigational study therapy works as a potential treatment in decreasing knee pain and improving knee function in people who have mild to moderate OA of the knee.

If you qualify and choose to join the ACTiVION-I clinical trial, you may be compensated for your time and reimbursed for travel. Additionally, you will receive possible access to a new investigational therapy, study support and monitoring by a healthcare team, education about OA, and the opportunity to advance OA research, all at no cost.

Who can join the ACTiVION-I clinical trial?

If you are experiencing knee and joint pain due to osteoarthritis, you may be able to join the ACTiVION-I clinical trial if you meet the following requirements:

  • Must be 40 years of age or older
  • Must have mild to moderate osteoarthritis that has been diagnosed in at least one knee (target knee)
  • You will be asked to rate your pain, mobility, and other symptoms during screening
  • Must not have pain so severe that it requires the use of a crutch, cane, prosthetic leg, or walker
  • Must not have had surgery on the target knee within the last six months or you are not planning or have scheduled total knee replacement surgery in the next 12 months
  • Have not had a major injury to the target knee within 12 months prior to screening

* Other study requirements will apply

What will happen during the ACTiVION-I clinical trial?

Participation in the ACTiVION-I  clinical trial lasts about 24 months and is divided into 3 periods with a long-term safety follow-up study:

Screening Period
Receive tests and assessments to confirm you qualify for the study, including blood and urine tests, imaging (X-ray and MRI) tests, and questionnaires.
Study Therapy
Receive a single injection of either the investigational study therapy or placebo (2:1 randomization ratio). You will remain at the study clinic for approximately 2 hours afterward so the study team can check your health.
Follow-up
Visit the study clinic for tests and assessments. You will have visits 1 day, 1 week, and 1 month after your injection, and then 6 times over the next 24 months.
Long-Term Follow-up
You will be asked to participate in a long-term safety follow-up study to monitor your progress for up to 15 years. If you do not want to participate in the long-term safety follow-up study, then you will be asked to answer questions about your health annually for 13 years after you receive your investigational study therapy or placebo injection.

Participation in this clinical trial is voluntary. You can ask any questions you have and may leave the study at any time, for any reason.

Interested in the ACTiVION-I clinical trial?

Take the short pre-screening questionnaire below to find out if you may qualify for the ACTiVION-I study. Because of the high interest in this OA clinical trial, kindly complete the pre-screener only one time.

Take the Pre-Screener

About the Investigational Study Therapy

What is the investigational study therapy?

The investigational study therapy (TG-C)  has a mixture of human chondrocyte cells and irradiated, transduced GP2-293 cells that are injected into the knee. The intended goal of this investigational therapy is to reduce pain and delay the progression of the disease through slowing cartilage degeneration.

The investigational study therapy will be given as an injection. A medical professional will carefully insert a needle into your knee using an imaging device to help guide them.

Will I receive the study therapy?

Participants will be randomized at a 2:1 ratio, where:

  • 2 out of every 3 participants will receive the study therapy (TG-C)
  • 1 out of every 3 will receive a placebo (no active ingredients)

Will this investigational therapy cure my knee pain so I don’t have to get a knee replacement?

Osteoarthritis is considered a chronic (long-lasting) disease, and other than joint replacement surgery, there is presently no cure.

Non-operative treatment can be effective if subjects are compliant with the treatment plan, which typically consists of self-management activities, including, but not limited to, weight loss (when necessary), exercise, and appropriate use of anti-inflammatory medication. When self-management becomes insufficient, multiple injections may be administered. Finally, if symptoms persist, surgical treatments and ultimately knee arthroscopy or arthroplasty may be recommended.

The investigational study therapy (TG-C) in ACTiVION-I is designed as a single-dose investigational therapy in subjects with a mild to moderate osteoarthritis of the knee. The intended goal of this investigational therapy is to reduce knee pain and delay the progression of the disease through slowing the loss of knee cartilage.

What is an “investigational medicine?”

Investigational means the study medication is not approved by regulatory authorities like the US Food and Drug Administration (FDA), and it can only be used in clinical research studies like the ACTIVION-I study.

About Osteoarthritis of the Knee

Osteoarthritis (OA) is the most common form of arthritis. It is a disease that affects all the tissues of the joint, including the cartilage, bone, ligaments, and muscles. It can develop in any number of joints, but most commonly affects the knees, hands, and hips. The symptoms of OA can vary in severity, but in its more severe forms OA is a painful condition that restricts mobility, interrupts sleep, and interferes with the sufferer’s enjoyment of life. OA of the knee is characterized by pain, swelling, and stiffness resulting from cartilage damage/loss in the joint. . There are several risk factors associated with the development of OA, but it is most often caused by natural "wear-and-tear” of the knee joint over time.

OA is considered a chronic (long-lasting) disease and other than joint replacement surgery there is presently no cure.

Symptoms can occur in episodes or consistently and  can turn simple daily tasks into difficult ones. These symptoms often develop slowly and worse over time. Symptoms of osteoarthritis of the knee include but are not limited to:

  • Knee pain/tenderness, even while performing easy tasks or while sitting still
  • Decreased function that may lead to the inability to bend and straighten your knee properly
  • Stiffness when first getting up in the morning or after sitting for an extended period
  • Swelling that causes the knee to appear puffy

Overview of Clinical Trials

Here are some common questions and answers about study participation.

If you have additional questions about participating in a clinical research study, talk to your doctor.

Study Clinic Locations

Find a study clinic near you!

The ACTiVION-I clinical trial currently has multiple doctors across the US now accepting participants to help identify a new potential treatment for people suffering with knee pain from mild to moderate osteoarthritis of the knee. If you'd like to learn more or are interested in participating in the ACTiVION-I trial, click below to fill out a brief questionnaire and get matched to the study clinic closest to

Take the Pre-Screener
Stock photos posed by models
Copyright © 2023 Medpace